Valion Bio
VBIO
8 hedge funds and large institutions have $233K invested in Valion Bio in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
97% more capital invested
Capital invested by funds: $119K → $233K (+$115K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
14% more funds holding
Funds holding: 7 → 8 (+1)
10.32% more ownership
Funds ownership: 4.64% → 14.96% (+10%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$89.9K |
| 2 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
+$62.6K |
| 3 |
HF
HRT Financial
New York
|
+$43.4K |
| 4 |
MG
Marex Group
London,
|
+$18.8K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$17.7K |
| 3 |
Citigroup
New York
|
-$7.25K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$19 |
VBIO Hedge Fund Activity: Q1 2026 in Review
8 of the 8,199 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2026, worth a combined $233K — up 97% from $119K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VBIO positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $89.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $21.2K sold.
- 8 institutional investors held Valion Bio (VBIO) as of Q1 2026, up from 7 in Q4 2025.
- Funds reported $233K of Valion Bio stock for Q1 2026, up 97% quarter-over-quarter.
- 4 funds opened new Valion Bio positions in Q1 2026 and 3 closed out, a net change of +1 holder.
- The largest Valion Bio buyer in Q1 2026 was Geode Capital Management, an estimated $89.9K added.
- The largest Valion Bio seller in Q1 2026 was Susquehanna International Group, an estimated $21.2K sold.
Based on aggregated 13F filings for Q1 2026.